1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with dibutyryl cyclic gmp in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (dibutyryl cyclic gmp) | Trials (dibutyryl cyclic gmp) | Recent Studies (post-2010) (dibutyryl cyclic gmp) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 551 | 0 | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barkin, M; Barnett, CC; Moore, EE; Offner, PJ; Partrick, DA; Silliman, CC | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and dibutyryl cyclic gmp
| Article | Year |
|---|---|
Nitric oxide attenuates platelet-activating factor priming for elastase release in human neutrophils via a cyclic guanosine monophosphate-dependent pathway.
Topics: Adult; Analysis of Variance; Cyclic GMP; Dibutyryl Cyclic GMP; Humans; In Vitro Techniques; Kinetics; Leukocyte Elastase; Models, Biological; Molsidomine; Neutrophils; Nitric Oxide; Platelet Activating Factor; Signal Transduction; Substrate Specificity | 1997 |